Edwards Lifesciences Corporation (EW) Earnings
Edwards Lifesciences Corporation is expected to report next earnings on July 23, 2026 (in NaN days), with a consensus EPS estimate of $0.73. EW has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +8.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 23, 2026 | $0.73 | $0.78 | +7.0% | $1.6B | +3.2% |
| Oct 30, 2025 | $0.60 | $0.67 | +12.4% | $1.6B | +3.7% |
| Jul 24, 2025 | $0.62 | $0.67 | +7.4% | $1.5B | +3.0% |
| Apr 23, 2025 | $0.60 | $0.64 | +7.4% | $1.4B | +0.9% |
| Oct 24, 2024 | $0.67 | $0.67 | +0.8% | $1.4B | -12.3% |
| Jul 24, 2024 | $0.69 | $0.70 | +1.4% | $1.4B | -16.2% |
| Apr 25, 2024 | $0.64 | $0.66 | +3.1% | $1.6B | +1.8% |
| Feb 6, 2024 | $0.64 | $0.64 | +0.0% | $1.5B | +2.7% |
| Oct 25, 2023 | $0.59 | $0.59 | +0.0% | $1.5B | +0.1% |
| Jul 26, 2023 | $0.65 | $0.66 | +1.5% | $1.5B | +1.8% |
| Jan 31, 2023 | $0.61 | $0.64 | +4.9% | $1.3B | +1.1% |
| Oct 27, 2022 | $0.62 | $0.61 | -1.6% | $1.3B | -1.1% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · April 23, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Building on strong 2025 performance, Q1 2026 achieved 12.7% self-growth. Focus on structural heart disease and innovation. Strategy underpinned by speed, agility, discipline. TAVR benefits from clinical focus on proactive disease management, long-term evidence of SAPIEN platform. TMTT's unique portfolio of therapies driving growth. Surgical expanding portfolio to address structural heart patients' needs. - Financial performance: Q1 sales growth strong, raised full-year sales guidance for total company and TAVR. Adjusted EPS guidance updated. Gross margin guidance maintained. R&D and SG&A expenses discussed.
Guidance
- Raised full-year 2026 total company sales guidance to 9%-11%, TAVR sales guidance to 7%-9%. - 2026 TMTT sales expected $740 - $780 million. Mid-single-digit sales growth expected in surgical. - Updated full-year earnings per share guidance to $2.95 - $3.05 per share. - Projected Q2 sales 1.66 - 1.74 billion dollars, adjusted earnings per share 70 cents - 76 cents.
Segment performance
TAVR: First quarter global sales of $1.2 billion, increased 11% year-over-year. U.S. sales healthy, international even faster. Full year TAVR self-growth guidance raised to 7-9%. TMTT: First quarter sales of $173 million, increase of approximately 42% year-over-year. Procedural growth in mitral and tricuspid in double digits. 2026 TMTT sales expected $740 - $780 million, 35-45% growth. Surgical: First quarter global sales of $276 million, increased 6% year-over-year. Continued adoption of Resilia therapies. Mid single digit sales growth expected in 2026.
Analyst Q&A
Q: David Roman with Goldman Sachs asked about TAVR industry data and drivers of guidance.
A: Discussed TAVR data like early TAVR for asymptomatic, 7-year and 10-year data, market growth and some share gain.
Q: Larry Beagleson with Wells Fargo asked about TAVR guidance and M3 impact.
A: TAVR guidance based on Q1 outperformance, market growth and some share. M3 launching in U.S. for tricuspid patients in Q4.
Q: Travis Seed with Bank of America asked about capacity and NCD.
A: Capacity managed well by health systems, NCD process ongoing.
Q: Robbie Marcus with JP Morgan asked about guidance rationale.
A: Guidance realistic based on Q1 performance, comps, and high bar from 2025 H2.
Q: Vijay Kumar with Evercore ISI asked about share count and weather impact.
A: Share count impacted by accelerated share repurchase, weather impact nominal.
Q: Joanne Wunsch with Citibank asked about R&D and CFO search.
A: R&D investment intentional, CFO search process ongoing.
Q: Matt Taylor with Jefferies asked about TAVR guidance and healthcare environment.
A: TAVR guidance based on Q1 outperformance and market growth, healthcare environment positive with RAPID policy.
Q: Matt Mixick with Barclays asked about Mitral rollout and TriGustin.
A: Sapien M3 rollout starting with clinical trial centers, details on Mitral and TriGustin engagement.